Cíl: 18 F-fluorestradiol je nové radiofarmakum, které lze použít při zobrazování karcinomu prsu, indikace v klinických postupech ještě nemají své pevné místo, proto je cílem studie posoudit klinický význam zobrazení karcinomu prsu estrogen-pozitivních receptorů (ER+) pomocí 18 F-fluorestradiolu (18 F-FES) PET/CT nebo PET/MR z hlediska využití při rozhodnutí o léčbě. Studie se zabývá také volbou využití PET/CT nebo PET/MR ve stagingu a restagingu karcinomu prsu. Metodika: U 40 pacientek s estrogen pozitivním karcinomem prsu bylo provedeno hybridní zobrazení s intravenózní aplikací 18 F-FES, ve 25 případech bylo použito PET/CT, v 15 případech PET/MR. Radiofarmakum bylo injekčně aplikováno v aktivitě 2,5 MBq/kg. U deseti pacientek byla jako restagingová metoda použito PET/ MR, v pěti případech stagingu před operací bylo provedeno PET/MR s cíleným plným diagnostickým MR zobrazením prsu v pronační poloze s následným zobrazením trupu v poloze na zádech. Všechna vyšetření PET/MR byla provedena po aplikaci gadoliniové kontrastní látky, zobrazení zahrnovalo zobrazení mozku v T1 STARVIBE. PET/CT bylo provedeno kontinuální PET akvizicí následně po akvizici CT s intravenózním podáním jodované kontrastní látky, v pěti případech bylo provedeno ve stagingu, ve 20 případech v restagingu. Výsledky: Nejdůležitějším výsledkem byla detekce ER+ metastáz při negativním výsledku 18 F-FDG-PET (12krát) – včetně mozkových a jaterních metastáz, perzistující ER+ metastáz (7krát), staging onemocnění (10krát), ztráta ER (4krát) a negativní nález pro metastázy (2), při pěti vyšetřeních nebyly nalezeny žádné přidané informace. Závěr: 18 F-FES-PET poskytuje klinicky vý- znamné informace pro volbu léčebné strategie, 18 F-FES-PET/MR je výhodné vyšetření při zaměření na zobrazení mozku a jater s možnos- tí prokázat anebo vyloučit metastázy v těchto orgánech.
Aim. 18 F-fluoroestradiol is a novel radiopharmaceutical useful in the imaging of breast carcinoma, the indications in clinical scenarios are under development. The purpose of the study is to assess the clinical impact of the imaging of the breast carcinoma with estrogenpositive receptors (ER+) using 18 F-fluoroestra- diol ( 18 F-FES) PET/CT or PET/MRI according to the treatment decision making. The study is concerned in the different preference of PET/CT and PET/MRI in the staging and restaging. Methods. 40 patients with estrogen positive breast carcinoma underwent the hybrid imaging after intravenous application of 18 F-FES, in 25 cases it was used PET/CT, in 15 cases PET/ MRI. The radiopharmaceutical was injected with the activity of 2,5 MBq/kg. In 10 patient, PET/MRI was used as restaging method, PET/ MRI was performed in the 5 cases of the staging before surgery with targeted full diagnostic MRI imaging of the breast in prone position, followed by the trunk imaging in supine position. All PET/MRI were performed after application of the gadolinium contrast material, the imaging included brain imaging in T1 STARVIBE. PET/CT was performed using the continuous PET acquisition after CT with the intravenous administration of the iodinated contrast material, in 5 cases was performed in staging, in 20 cases in restaging Results. The most important informa- tion was detection of ER+ metastases when 18 F-FDG-PET was negative (12×) – including brain and liver metastases, the persistent ER+ of the metastases (7×), staging of the disease (10×), the loss of the ER (4x) and the negative finding for metastases (2), no added information was found in 5 examinations. Conclusion. 18 F-FES-PET provided the impor- tant clinical information to treatment strategy, 18 F-FES-PET/MRI improves the imaging of metastases in brain and liver.
PURPOSE: We aimed to find predictive tumour characteristics as detected by interim positron-emission tomography/magnetic resonance imaging (PET/MRI) in cervical cancer patients. We also investigated the type of interim response. Furthermore, we compared the investigated parameters with disease-free (DFS) and overall survival (OS) outcomes. METHODS: We evaluated 108 patients treated between August 2015 and January 2023 with external-beam radiotherapy (EBRT) and image-guided adaptive brachytherapy (IGABT) who had undergone pretreatment staging, subsequent mid-treatment evaluation after completed EBRT and definitive restaging 3 months after completing the whole treatment using PET/MRI. Patients were then divided into two groups based on the RECIST and PERCIST criteria: responders (achieving complete metabolic response, CMR) and non-responders (non-CMR). These two groups were compared using selected parameters obtained at pre-PET/MRI and mid-PET/MRI. The early response to treatment as evaluated by mid-PET/MRI was categorized into three types: interim complete metabolic response, interim nodal response and interim nodal persistence. RESULTS: Mid-TLG‐S (the sum of total lesion glycolysis for the primary tumour plus pelvic and para-aortic lymph nodes) parameter showed the best discriminatory ability for predicting non-CMR. The second factor with significant discriminatory ability was mid-MTV‐S (the sum of the metabolic tumour volume of the primary tumour plus pelvic and para-aortic lymph nodes). The strongest factor, mid-TLG‐S, showed a sensitivity of 40% and a specificity of 90% at a threshold value of 70. We found a statistically significant association of DFS and OS with the following parameters: number of chemotherapy cycles, early response type and CMR vs. non-CMR. CONCLUSION: We were able to identify thresholds for selected parameters that can be used to identify patients who are more likely to have worse DFS and OS. The type of early response during concurrent chemoradiotherapy (CCRT) was also significantly associated with DFS and OS. These aspects represent an important contribution to the possible stratification of patients for subsequent individualised adjuvant treatment.
- MeSH
- Brachytherapy MeSH
- Chemoradiotherapy * methods MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Magnetic Resonance Imaging * MeSH
- Multimodal Imaging * MeSH
- Uterine Cervical Neoplasms * therapy diagnostic imaging pathology mortality MeSH
- Positron-Emission Tomography * MeSH
- Disease-Free Survival MeSH
- Radiotherapy, Image-Guided MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Prezentujeme kazuistiku 69letého muže, u něhož byl při ultrazvukovém vyšetření urotraktu náhodně zachycen suspektní 30mm útvar v oblasti levé nadledviny, na základě zobrazovacích vyšetření nebylo možné vyloučit maligní potenciál nálezu. Pacient byl indikován k levostranné adrenalektomii, histologickým nálezem byl středně diferencovaný ohraničený leiomyosarkom, nadledvina byla bez infiltrace. Pacient byl bez známek generalizace, na základě doporučení multidisciplinárního onkologického týmu je zařazen do sledování, kontrolní restagingové CT proběhlo šest měsíců od výkonu s negativním nálezem.
We describe a case report of a 69-year-old male with suspicious 30 mm mass in the area of left adrenal gland detected on ultrasound examination. Based on imaging examinations it was not possible to rule out a malignant potential of the lesion. The patient underwent left side adrenalectomy, the histological examination revealed a moderately differentiated, well-circumscribed leiomyosarcom. The adrenal gland was without infiltration. There were no signs of metastatic disease. According to the recommendation of multidisciplinary oncology team, he is placed under surveillance. The patient underwent a follow-up restaging CT 6 months after the surgery with negative results.
- MeSH
- Adrenalectomy methods MeSH
- Leiomyosarcoma * surgery diagnosis pathology MeSH
- Humans MeSH
- Adrenal Glands pathology MeSH
- Neoplasms, Connective and Soft Tissue pathology therapy MeSH
- Tomography, X-Ray Computed MeSH
- Retroperitoneal Neoplasms surgery diagnosis pathology MeSH
- Aged MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Case Reports MeSH
PURPOSE: A re-transurethral resection of the bladder (re-TURB) is a well-established approach in managing non-muscle invasive bladder cancer (NMIBC) for various reasons: repeat-TURB is recommended for a macroscopically incomplete initial resection, restaging-TURB is required if the first resection was macroscopically complete but contained no detrusor muscle (DM) and second-TURB is advised for all completely resected T1-tumors with DM in the resection specimen. This study assessed the long-term outcomes after repeat-, second-, and restaging-TURB in T1-NMIBC patients. METHODS: Individual patient data with tumor characteristics of 1660 primary T1-patients (muscle-invasion at re-TURB omitted) diagnosed from 1990 to 2018 in 17 hospitals were analyzed. Time to recurrence, progression, death due to bladder cancer (BC), and all causes (OS) were visualized with cumulative incidence functions and analyzed by log-rank tests and multivariable Cox-regression models stratified by institution. RESULTS: Median follow-up was 45.3 (IQR 22.7-81.1) months. There were no differences in time to recurrence, progression, or OS between patients undergoing restaging (135 patients), second (644 patients), or repeat-TURB (84 patients), nor between patients who did or who did not undergo second or restaging-TURB. However, patients who underwent repeat-TURB had a shorter time to BC death compared to those who had second- or restaging-TURB (multivariable HR 3.58, P = 0.004). CONCLUSION: Prognosis did not significantly differ between patients who underwent restaging- or second-TURB. However, a worse prognosis in terms of death due to bladder cancer was found in patients who underwent repeat-TURB compared to second-TURB and restaging-TURB, highlighting the importance of separately evaluating different indications for re-TURB.
Zobrazení vlastní tkáně nádoru prostaty je při použití postupů zobrazení obvyklých u jiných nádorů obtížné, nedostatečné je používat metody zobrazení pomocí kontrastního CT vyšetření, z hybridních metod také PET/CT s aplikací 18F-fluorodeoxyglukózy. Magnetickou rezonanci je možné využít v detekci karcinomu prostaty u mužů s elevací prostatického specifického antigenu (PSA) a/nebo zvýšeným indexem zdravé prostaty (PHI). V současnosti je možné využití spojení radiologických metod a nukleární medicíny - výpočetní tomografie a pozitronové emisní tomografie (PET/CT) nebo magnetické rezonance a pozitronové emisní tomografie (PET/MR). Pro pozitronovou emisní tomografii je možné využití 18F-fluorocholinu (18F-FCH), 18F-fluciclovinu, a 18F-natriumfluoridu (18F-NaF) nebo 68Ga-PSMA-11 (ligand prostatického specifického membránového antigenu), a to ve vyhledávání, stagingu a restagingu karcinomu prostaty. PET/MR nebo PET/CT s podáním 68Ga-PSMA-11 představuje současnou optimální metodu při stagingu, restagingu a kontrole účinku terapie karcinomu prostaty.
Imaging of the prostate tumour ́s own tissue is using standard tumour imaging approaches remains difficult, the imaging using contrast enhanced computed tomography and also the hybrid imaging using PET/CT with the application of the 18F-fluorodeoxyglucose is insufficient. Magnetic resonance imaging is useful in detection of prostate cancer in patients with elevated prostatic specific antigen (PSA) and/or with increased prostate health index (PHI). Currently, it is possible to use combination of radiological and nuclear medicine methods - hybrid positron emission tomography combined with computed tomography (PET/CT) or with magnetic resonance imaging (PET/MRI) with the application of 18F-fluorocholine (FCH), 18F-fluciclovine, 18F-natriumfluoride (18F-NaF) or 68Ga-PSMA-11 (ligand of prostatic specific membrane antigen) in detection, staging or restaging of prostate carcinoma. PET/CT or PET/MRI with the application of 68Ga-PSMA-11 represents current optimal method for staging, restaging and evaluation of prostate cancer therapy response.
- MeSH
- Diagnostic Imaging classification methods MeSH
- Fluorodeoxyglucose F18 therapeutic use MeSH
- Humans MeSH
- Magnetic Resonance Imaging methods MeSH
- Multimodal Imaging * classification methods MeSH
- Prostatic Neoplasms * diagnostic imaging diagnosis MeSH
- Positron Emission Tomography Computed Tomography methods MeSH
- Prostate-Specific Antigen analysis MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Kazuistika představuje případ 78letého pacienta, u kterého byl diagnostikován malobuněčný karcinom pravé plíce, ED (extensive disease), T4N2M0. Pacient byl indikován k chemoterapii karboplatinou a etoposidem. Radioterapie nebyla indikována pro rozsah postižení. Od druhého cyklu po schválení centrové léčby byl přidán durvalumab. Restagingové vyšetření výpočetní tomografií prokázalo regresi základního onemocnění, zároveň ale byl zjištěn duplicitní adenokarcinom kolon. Pacient podstoupil pravostrannou hemikolektomii, pT3pN0 (0+/18) Mx. Po krátkém přerušení terapie v době zotavování po resekčním výkonu nadále pokračuje v terapii durvalumabem s dobrým léčebným účinkem. U pacienta přes vyšší věk trvá dobrý výkonnostní stav.
The report presents the case of a 78-year-old patient, diagnosed with small cell carcinoma of the right lung, ED (extensive disease), T4N2M0. The patient was selected for chemotherapy with carboplatin and etoposide. Radiotherapy was not applied due to the extent of pulmonary impairment. Durvalumab was added in second cycle. During the first computed tomography scan restaging, a duplicity of an adenocarcinoma of the colon was detected. Patient underwent right-sided hemicolectomy, pT3pN0 (0/18) Mx. After a short interruption of immuno-therapy, he continues with application of durvalumab with a good therapeutic effect. Despite the advanced age, the patient is in good condition.
AIM: The aim of this study was to analyse the outcomes of patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor T-cell therapy (CAR-Tx), with a focus on outcomes after CAR T-cell failure, and to define the risk factors for rapid progression and further treatment. METHODS: We analysed 107 patients with LBCL from the Czech Republic and Slovakia who were treated in ≥3rd-line with tisagenlecleucel or axicabtagene ciloleucel between 2019 and 2022. RESULTS: The overall response rate (ORR) was 60%, with a 50% complete response (CR) rate. The median progression-free survival (PFS) and overall survival (OS) were 4.3 and 26.4 months, respectively. Sixty-three patients (59%) were refractory or relapsed after CAR-Tx. Of these patients, 39 received radiotherapy or systemic therapy, with an ORR of 22% (CR 8%). The median follow-up of surviving patients in whom treatment failed was 10.6 months. Several factors predicting further treatment administration and outcomes were present even before CAR-Tx. Risk factors for not receiving further therapy after CAR-Tx failure were high lactate dehydrogenase (LDH) levels before apheresis, extranodal involvement (EN), high ferritin levels before lymphodepletion (LD) and ECOG PS >1 at R/P. The median OS-2 (from R/P after CAR-Tx) was 6.7 months (6-month 57.9%) for treated patients and 0.4 months (6-month 4.2%) for untreated patients (p < 0.001). The median PFS-2 (from R/P after CAR-Tx) was 3.2 months (6-month 28.5%) for treated patients. The risk factors for a shorter PFS-2 (n = 39) included: CRP > limit of the normal range (LNR) before LD, albumin < LNR and ECOG PS > 1 at R/P. All these factors, together with LDH > LNR before LD and EN involvement at R/P, predicted OS-2 for treated patients. CONCLUSION: Our findings allow better stratification of CAR-Tx candidates and stress the need for a proactive approach (earlier restaging, intervention after partial remission achievement).
- MeSH
- Antigens, CD19 immunology MeSH
- Biological Products therapeutic use MeSH
- Receptors, Chimeric Antigen immunology MeSH
- Lymphoma, Large B-Cell, Diffuse * therapy mortality immunology MeSH
- Progression-Free Survival MeSH
- Adult MeSH
- Immunotherapy, Adoptive * methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local MeSH
- Young Adult MeSH
- Disease Progression MeSH
- Receptors, Antigen, T-Cell genetics metabolism MeSH
- Risk Factors MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
- Slovakia MeSH
BACKGROUND: The European Association of Urology guidelines include the lutetium-177 (177Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy option for metastatic castration-resistant prostate cancer (mCRPC). A major challenge in clinical practice is to pursue a personalized treatment approach based on robust predictive biomarkers. OBJECTIVE: To assess the performance of 177Lu PSMA in real-world practice and to elaborate clinical biomarkers for evaluating treatment responses. DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective observational study including 233 patients with mCRPC treated with 177Lu PSMA in eight high-volume European centers. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Baseline characteristics and clinical parameters during and after 177Lu PSMA treatment were documented. Correlations to treatment response were analyzed using χ2 and log-rank tests, with differences between groups with and without disease progression calculated using a Mann-Whitney U test. Univariate and multivariate-adjusted hazard ratios (HRs) were measured using Cox proportional hazards models. RESULTS AND LIMITATIONS: A prostate-specific antigen (PSA) decrease of ≥30% was observed in 41.7%, 63.5%, and 77.8% of patients after the first, second, and third treatment cycle, respectively. Restaging performed via PSMA positron emission tomography-computed tomography revealed that 33.7% of patients had an imaging-based response, including two patients with a complete response, while 13.4% had stable disease. The median time to progression was 5 mo and the median time until the start of a consecutive antineoplastic therapy was 8.5 mo. Of importance, a PSA decrease ≥30% after the first two cycles of 177Lu PSMA (1 cycle: p = 0.0003; 2 cycles: p = 0.004), absolute PSA after the first three cycles (1 cycle: p = 0.011; 2 cycles: p = 0.0005; 3 cycles: p = 0.002), and a PSA doubling time >6 mo (p = 0.009) were significantly correlated to treatment response. Furthermore, gamma-glutamyl transferase ≤31 U/L at the start of 177Lu PSMA therapy was correlated with 1.5 times higher risk of progression for patients without but not with visceral metastases (p = 0.046). CONCLUSIONS: 177Lu PSMA is an effective treatment option in mCRPC in the real-world setting. A PSA decrease ≥30% after the first two cycles is an early marker of response that can be easily implemented in clinical practice. PATIENT SUMMARY: 177Lu PSMA is a radioactive agent approved for treatment of advanced prostate cancer. We reviewed its use outside of clinical trials for patients treated at eight European centers. We found that 177Lu PSMA is an effective treatment option in real-world practice. A PSA (prostate-specific antigen) decrease of ≥30% after the first two therapy cycles is an early indicator of response to treatment and can be used in personalizing treatments for patients.
- MeSH
- Antigens, Surface metabolism MeSH
- Glutamate Carboxypeptidase II metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Ligands MeSH
- Lutetium * therapeutic use MeSH
- Neoplasm Metastasis MeSH
- Biomarkers, Tumor blood MeSH
- Prostatic Neoplasms, Castration-Resistant * pathology radiotherapy drug therapy MeSH
- Prostate-Specific Antigen blood MeSH
- Radioisotopes therapeutic use MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Geographicals
- Europe MeSH
Východiska: Uveální melanom je velmi vzácným nádorem, který asi v polovině případů metastazuje. V případě rozvoje metastatického onemocnění je jeho prognóza krajně nepříznivá a medián přežití nepřesahuje 6 měsíců. Možnosti účinné léčby byly doposud velmi limitované. Tebentafusp je bispecifickým fúzním proteinem, který jako první prokázal účinnost u uveálního melanomu. Případ: Pacientka odeslaná pro suspektní melanom levého oka byla dříve léčena pro Hodgkinovu nemoc. Primárně byl nádor ošetřen radiochirurgicky s radioterapií drobného ložiska obratlového těla. Následně však pacientka musela podstoupit enukleaci bulbu s nálezem rozsáhlého tumoru pT4b. PET/CT prokázala metastázy skeletu a jater, zároveň byl prokázán haplotyp A*02: 01. Pacientka absolvovala radioterapii sterna a následně – po schválení léku na základě žádosti na §16 – zahájila léčbu preparátem tebentafusp. Lék byl v prvních třech dávkách podáván za hospitalizace s nutností léčby cytokine release syndromu kortikosteroidy. Následně probíhala aplikace týdně ambulantní formou bez komplikací krom tranzitorní elevace transamináz. První restaging CT po 3 měsících prokázala stabilní nemoc, zatímco druhé restaging CT prokázala novou osteolytickou lézi ve výběžku Th11. Z důvodu progrese byla léčba tebentafuspem po 6 měsících ukončena. Ložisko bohužel nebylo možno ošetřit radioterapií. Po 2 měsících byla pacientka urgentně hospitalizována pro pravostrannou hemiplegii a MR prokázala prokrvácené metastatické ložisko v mozkovém kmeni. Závěr: V této kazuistice popisujeme případ první pacientky léčené tímto lékem v ČR.
Background: Uveal melanoma is a rare cancer, in which metastases occur in approximately one half of cases. In metastatic disease, the prognosis is unfavorable and the median of survival does not exceed 6 months. Effective treatment options were very limited up to date. Tebentafusp is a bispecific fusion protein, which as the first drug proved efficacy in uveal melanoma. Case: The patient was referred for suspected uveal melanoma of the left eye. She was treated for Hodgkin’s disease in the past. Primarily, the tumor was treated by radiosurgery with radiotherapy of a small lesion of the vertebral body. However, later the patient had to undergo bulbus enucleation with confirmation of a large tumor category pT4b. PET/CT revealed metastases of the bones and the liver; simultaneously, haplotype A*02: 01 was confirmed. The patient underwent radiotherapy of the sternum and later, after confirmation of payment from the health insurance company, she started treatment with tebentafusp. The first three doses were administered during admission to the hospital, with a need to treat cytokine release syndrome by corticosteroids. Later, the administration was performed in an out-patient regimen, without complications, except for a transient elevation of transaminases. The first CT restaging confirmed stable disease; however, the second restaging confirmed a new osteolytic lesion in the processus of Th11. Because of progression, the treatment with tebentafusp was withdrawn after 6 months. Unfortunately, the lesion could not be treated by radiotherapy. Two months later, the patient was urgently admitted to the hospital because of right-sided hemiplegia; MRI revealed bleeding metastatic lesion in the brain stem. Conclusion: In this case report, we present the case of the first patient treated with this drug in the Czech Republic.
- Keywords
- tebentafusp,
- MeSH
- Eye Enucleation MeSH
- Fatal Outcome MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Metastasis diagnostic imaging radiotherapy MeSH
- Uveal Neoplasms * diagnostic imaging complications pathology therapy MeSH
- Treatment Failure MeSH
- Positron Emission Tomography Computed Tomography MeSH
- Disease Progression MeSH
- Recombinant Fusion Proteins * administration & dosage economics adverse effects MeSH
- Neoplasms, Second Primary diagnostic imaging therapy MeSH
- Cytokine Release Syndrome chemically induced drug therapy MeSH
- Ultrasonography MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Case Reports MeSH
INTRODUCTION: The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD). METHODS: Guidelines were developed according to AGREE II and GRADE principles. Guidelines were based on a systematic review (OMEC-1), clinical case discussions (OMEC-2), and a Delphi consensus study (OMEC-3) by 49 European expert centers for esophagogastric cancer. OMEC identified patients for whom the term OMD is considered or could be considered. Disease-free interval (DFI) was defined as the time between primary tumor treatment and detection of OMD. RESULTS: Moderate to high quality of evidence was found (i.e. 1 randomized and 4 non-randomized phase II trials) resulting in moderate recommendations. OMD is considered in esophagogastric cancer patients with 1 organ with ≤ 3 metastases or 1 involved extra-regional lymph node station. In addition, OMD continues to be considered in patients with OMD without progression in number of metastases after systemic therapy. 18F-FDG PET/CT imaging is recommended for baseline staging and for restaging after systemic therapy when local treatment is considered. For patients with synchronous OMD or metachronous OMD and a DFI ≤ 2 years, recommended treatment consists of systemic therapy followed by restaging to assess suitability for local treatment. For patients with metachronous OMD and DFI > 2 years, upfront local treatment is additionally recommended. DISCUSSION: These multidisciplinary European clinical practice guidelines for the uniform definition, diagnosis and treatment of esophagogastric OMD can be used to standardize inclusion criteria in future clinical trials and to reduce variation in treatment.
- MeSH
- Delphi Technique MeSH
- Consensus MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Esophageal Neoplasms * therapy pathology diagnosis MeSH
- Stomach Neoplasms * therapy pathology diagnosis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Practice Guideline MeSH
- Systematic Review MeSH
- Geographicals
- Europe MeSH